Just three weeks after announcing its plans for a U.S. listing, Belgium-based Agomab has gone public on Nasdaq after pricing its IPO at $16 per share, aiming to bring in about $200 million in gross proceeds with its stock now trading under the ticker AGMB.
Swedish clinical-stage pharmaceutical company Vicore Pharma has secured SEK100m, supported by existing and new investors. The injection of capital will allow the company to scale the clinical development of its portfolio of therapies in respiratory and fibrotic diseases.
Despite the recent stock market rally and declining volatility, IPOs are rather rare in many industrialised countries –not least for seasonal reasons. The main reason for this, however, is the aggressive monetary policy of the central banks, with more than ten interest rate hikes in both Europe and the US.
The eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp.
AI via Freepik
Sphene Capital